COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?

The aim: to reflect the features of the course of irritable bowel syndrome during the COVID-19 pandemic. Key points. It has been noted that the COVID-19 may contribute to the formation of post-infectious functional gastrointestinal diseases, given that angiotensin-converting enzyme-2 (ACE-2) receptors, the site of binding of the SARS-CoV-2 virus to human cells, are also present in epithelial intestinal cells;virus was found in feces in about half of patients, gastrointestinal symptoms, including diarrhea occur in about one fifth of patients, fecal calprotectin, a marker of GI inflammation is elevated in patients with COVID-19, macroscopically as well as histologically, patients show signs of damage mucous membrane of the gastrointestinal tract, and also, as noted above, they have a dysbiosis of the intestinal microbiota. Conclusion. It was shown that during the pandemic, more than 90 % of the interviewed patients with IBS had an exacerbation of IBS with an increase in symptoms such as bloating and cramps, and 75 % of them said that the exacerbation of symptoms was reflected in the activity of patients in everyday life. These factors dictate the need for an integrated approach in the management of such a group of patients with the use of modern multi-target drugs that affect the pathogenetic factors in the formation of functional gastrointestinal diseases, one of which is the Kolofort drug due to the triple multi-target mechanism of action on the pathogenesis of functional gastrointestinal diseases. © 2022 Russian Journal of Neurosurgery.

[Correction of intestinal microbial composition disturbances as a potential link in complex therapy of patients with COVID-19].

The article reflects the potential for correcting intestinal microbiota disorders in the complex therapy of patients with COVID-19. It has been noted that the inclusion of dietary fiber in the diet contributes to protection against disruption of the integrity of the intestinal barrier and may limit bacterial translocation into the systemic circulation. The possibility of using psyllium (Mucofalk) is reflected, the action of which is realized both through its sorption, cytoprotective and anti-inflammatory properties in viral lesions of the gastrointestinal tract, and through stimulation of the own beneficial intestinal microbiota. The paper presents studies of the prospects for the use of probiotics, synbiotics in the complex therapy of patients with COVID-19. Detailed data are provided on the mechanisms of the positive effect of short-chain fatty acid preparations on reducing the severity of the disease in patients with COVID-19. It was noted that taking the drug Zacofalk leads to a significant increase in its own butyrate-producing microbiota (Faecalibacterium prausnitzii) and suppression of the growth of opportunistic flora with pro-inflammatory activity. The results of a recent study are presented showing that in patients with a mild course of COVID infection with respiratory and intestinal symptoms, the administration of Zakofalk for 30 days (3 tablets per day) led to significantly faster stool normalization (by day 7), persistent normalization of the frequency and consistency of stools by the 21st day and a significantly more pronounced regression of bloating and abdominal pain, as well as a decrease in the risk of developing post-infectious irritable bowel syndrome.

Features of the liver condition at parients with a new COVID-19 infection

COVID-19 or Coronavirus disease-19 is an acute infectious disease caused by the SARS-Cov-2 coronavirus (Severe Acute Respiratory Syndrome CoronaVirus 2). This review article highlights the most important extra-pulmonary possible consequences of a new viral infection, with the main focus on liver damage. Evaluation criteria are described - at the stages of treatment and in the early rehabilitation period in patients with COVID-19 according to the recent scientific articles. © 2021 Stavropol State Medical University. All rights reserved.

Russian Consensus “Hyperammonemia in Adults” (Version 2021)

Given the large number of reports on the peculiarities of liver lesions during the Sars-Cov-2 infection [1], a team of experts who participated in the 23rd Congress of the Scientific Society of Gastroenterologists of Russia and 15 National Congress of Therapists of November 19, 2020 decided to make additions to the Russian Consensus of “Hyperammonemia in Adults” published early 2020 [2, 3]. © 2021 Global Media Tekhnologii. All rights reserved.